Overview

Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Zoledronic acid is a medication that slows the breakdown of bone. This study will assess the efficacy and safety of zoledronic acid in Chinese patients with multiple myeloma or other solid tumors with bone metastases.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novartis
Treatments:
Diphosphonates
Zoledronic Acid
Criteria
Inclusion Criteria

- Cancer patients (multiple myeloma or other solid tumors) and confirmed evidence of
bone lesions

- Significant bone pain

Exclusion Criteria

- Poor renal function

- Use of other investigational drugs within 30 days of visit 2

- Dental or other surgery to the jaw within 6 weeks of screening, or planned during the
4 week study

Other protocol-defined exclusion criteria may apply.